Loading company…
Therasid Bioscience develops drug candidates for non-alcoholic steatohepatitis.
Founded in 2017 and based in Gyeonggi-do, South Korea, Therasid Bioscience develops treatments for non-alcoholic steatohepatitis (NASH). Its liver-cell-based platform supports a pipeline ranging from early research to clinical stages, including TB-840, TB-RB, TB-DK, and TB-IH. The company raised an undisclosed amount in angel funding in June 2018 and KRW 6 billion in Series A funding in June 2019.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in